Category Archives: pharmaceuticals
August 21, 2018 | FAH Policy Blog Team
Category: FAH News, Legislation, Pharmaceuticals
Rising and excessive drug prices threaten patient access to the drugs they need and can undermine the care physicians see as necessary for patients. The Grassley-Durbin amendment (#3787) would take a great leap forward in providing consumers useful information on drug prices that could help them buy smart. And, the public display of prices could put a spotlight on those high prices and bring them down.
July 17, 2018 | FAH Policy Blog Team
Category: Pharmaceuticals, Transparency
The Federation of American Hospitals (FAH) sent a letter Monday to HHS Secretary Alex Azar commenting on the agency’s recently released Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
June 07, 2018 | FAH Policy Blog Team
Category: FAH News, Legislation, Medicare, Pharmaceuticals
A wide ranging coalition of 46 groups, that include FAH, from across the health care spectrum sent a letter today to leaders of the Senate Judiciary Committee urging swift action on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974).
March 16, 2018 | FAH Policy Blog Team
Category: Legislation, Pharmaceuticals
FAH sent a letter today to leaders on the House Ways and Means Committee highlighting policy changes that would help in battling the opioid epidemic.
Reps. Kevin Brady (R-TX), Richard Neal (D-MA), Peter Roskam (R-IL) and Sander Levin (D-MI) recently asked stakeholders to share their thoughts on ways to fight the crisis.
- Public Charge Rule Could Have Chilling Effect on Access to Care
- REPORT: A Medicare Public Option Puts Majority of Rural Hospitals at Risk
- In the News – FAH’s Study on Modernizing the HCAHPS Patient Experience Survey
- Joint Statement from National Hospitals Associations on Proposed CY 2020 OPPS Rule